Other receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) family and the platelet-derived growth factor-β receptor (PDGFRβ), have also been linked to neuroblastoma pathogenesis,7,11,15,41,42 suggesting that kinase inhibitors such as regorafenib that are able to target multiple critical kinases are likely to be effective against neuroblastoma, and further studies are needed to clarify the relative roles of these kinases in the responses of neuroblastoma tumours to regorafenib. The gene discussed is KDR; the disease is neuroblastoma.